Evotec to Report Results for the First Nine Months of 2013 on 12 November 2013
06 November 2013 - 8:00PM
Evotec AG (Frankfurt:EVT) (TecDAX) (ISIN:DE0005664809) will report
its financial results for the first nine months of 2013 on Tuesday,
12 November 2013.
The Company is going to hold a conference call to discuss the
results as well as to provide an update on its performance:
Conference call details
Date: |
Tuesday, 12 November
2013 |
Time: |
09.30 am CET (08.30 am GMT, 03.30 am
EST) |
|
|
|
|
From Germany: |
+49 (0) 6103 485 3001 |
From UK: |
+44 207 153 2027 |
From USA: |
+1 888 457 4228 |
Access Code: |
4645643 |
A simultaneous slide presentation for participants dialling in
via phone is available at www.equitystory.com, password:
evotec1113.
Webcast details
To join the audio webcast and to access the presentation slides
you will find a link on our home page www.evotec.com shortly before
the event.
A replay of the conference call will be available for 24 hours
and can be accessed in Europe by dialling +49 69 58 99 90 568
(Germany) or +44 207 154 2833 (UK) and in the US by dialling +1 303
590 3030. The access code is 4645643#. The on-demand version of the
webcast will be available on our website:
http://www.evotec.com/article/en/Investors/Finance/Financial-Reports-2011-2013/188/6/26.
ABOUT EVOTEC
AG
Evotec is a drug discovery alliance and development partnership
company focused on rapidly progressing innovative product
approaches with leading pharmaceutical and biotechnology companies.
We operate worldwide providing the highest quality stand-alone and
integrated drug discovery solutions, covering all activities from
target-to-clinic. The Company has established a unique position by
assembling top-class scientific experts and integrating
state-of-the-art technologies as well as substantial experience and
expertise in key therapeutic areas including neuroscience, pain,
metabolic diseases as well as oncology and inflammation. Evotec has
long-term discovery alliances with partners including Bayer,
Boehringer Ingelheim, CHDI, Genentech, Janssen Pharmaceuticals,
MedImmune/AstraZeneca and Ono Pharmaceutical. In addition, the
Company has existing development partnerships and product
candidates both in clinical and pre-clinical development. These
include partnerships with Boehringer Ingelheim, MedImmune and
Andromeda (Teva) in the field of diabetes, with Janssen
Pharmaceuticals in the field of depression and with Roche in the
field of Alzheimer's disease. For additional information please go
to www.evotec.com.
FORWARD LOOKING STATEMENTS— Information set
forth in this press release contains forward-looking statements,
which involve a number of risks and uncertainties. The
forward-looking statements contained herein represent the judgement
of Evotec as of the date of this report. Such forward-looking
statements are neither promises nor guarantees, but are subject to
a variety of risks and uncertainties, many of which are beyond our
control, and which could cause actual results to differ materially
from those contemplated in these forward-looking statements. We
expressly disclaim any obligation or undertaking to release
publicly any updates or revisions to any such statements to reflect
any change in our expectations or any change in events, conditions
or circumstances on which any such statement is based.
CONTACT: Gabriele Hansen
Head of Corporate Communications
+49.(0)40.560 81-255
+49.(0)40.560 81-222 Fax
gabriele.hansen@evotec.com
Evotec AG
Manfred Eigen Campus
Essener Bogen 7
22419 Hamburg (Germany)
Eaton Vance Tax Advantag... (NYSE:EVT)
Historical Stock Chart
From Jun 2024 to Jul 2024
Eaton Vance Tax Advantag... (NYSE:EVT)
Historical Stock Chart
From Jul 2023 to Jul 2024